Search
  • All Journals
Advanced Search
Search articles by Title, Author, Keywords, DOI
Submit Manuscript
0.7Impact Factor
Advanced Search
MAP  >  Gastrointestinal Tumors
2020 Volume 7
Article Contents
Next Previous
RESEARCH ARTICLE   Open Access    

Yttrium-90 Radioembolization Therapy for Combined Hepatocellular and Cholangiocarcinoma

  • a.

    Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA

  • b.

    Section of Interventional Radiology, University of Chicago, Chicago, IL, USA

More Information
  • Corresponding author: Wali Badar Chicago Medical School, Rosalind Franklin University 3300 Green Bay Road North Chicago 60064 (USA) wali.badar@my.rfums.org 
  • Purpose: To report outcomes of transarterial radioembolization (TARE) using glass microspheres for the treatment of mixed hepatocellular-cholangiocarcinoma (HCC-CC) in a propensity-matched study.
    Material and Methods: Between 2013 and 2019, 10 consecutive patients with histologically confirmed HCC-CC received TARE of a targeted territory using glass microspheres as a primary initial treatment. Baseline demographics in addition to tumor distribution, Child Pugh score, and BCLC were recorded. Tumor response was assessed according to modified RECIST criteria. The HCC-CC cohort was matched to the HCC cohort, and objective response and survival analysis was performed.
    Results: In the HCC-CC cohort, patients had a 70% objective response rate (ORR), and in the HCC cohort, patients had a 90% ORR after matching (p = 0.54). The median overall survival (OS) for HCC patients was 12.3 months (95% CI: 6.0–17.4 months) in the matched population, and for HCC-CC patients, the median OS was 15.2 months (95% CI: 2.7–20.2 months) (p = 0.98). The median progression-free survival (PFS) for HCC patients was 11.6 months (95% CI: 2.53–19.3 months) in the matched population, and for HCC-CC patients, the median PFS was 15.2 months (95% CI: 2.7–20.2 months) (p = 0.94). The median transplant-free survival (TFS) for HCC patients was 12.3 months (95% CI: 6.0–17.4 months) in the matched population, and for HCC-CC patients, the median TFS was 15.2 months (95% CI: 2.7–20.2 months) (p = 0.98).
    Conclusions: While outcomes of combined HCC-CC are poor and optimal treatment remains undefined, TARE appears to represent an effective locoregional treatment with survival outcomes similar to that of HCC treated by TARE.

  • Cite this article

    Wali Badar, Thuong Van Ha, Steven Zangan, Rakesh Navuluri, Anjana Pillai, Talia Baker, Osman Ahmed. 2020. Yttrium-90 Radioembolization Therapy for Combined Hepatocellular and Cholangiocarcinoma. Gastrointestinal Tumors. 7:8386 doi: 10.1159/000508386
    Wali Badar, Thuong Van Ha, Steven Zangan, Rakesh Navuluri, Anjana Pillai, Talia Baker, Osman Ahmed. 2020. Yttrium-90 Radioembolization Therapy for Combined Hepatocellular and Cholangiocarcinoma. Gastrointestinal Tumors. 7:8386 doi: 10.1159/000508386
    shu

Figures(2)  /  Tables(2)

Download PDF

Article Metrics

Article views(797) PDF downloads(469)

Other Articles By Authors

Research Article   Open Access    

Yttrium-90 Radioembolization Therapy for Combined Hepatocellular and Cholangiocarcinoma

  • a.

    Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA

  • b.

    Section of Interventional Radiology, University of Chicago, Chicago, IL, USA

  • Corresponding author: Wali Badar Chicago Medical School, Rosalind Franklin University 3300 Green Bay Road North Chicago 60064 (USA) wali.badar@my.rfums.org 
  • Received: 06 March 2020
  • Accepted: 27 April 2020
  • Published online: 28 July 2020
Gastrointestinal Tumors  7,  Article number: 10.1159/000508386  (2020)  |  Cite this article

Abstract: 

Purpose: To report outcomes of transarterial radioembolization (TARE) using glass microspheres for the treatment of mixed hepatocellular-cholangiocarcinoma (HCC-CC) in a propensity-matched study.
Material and Methods: Between 2013 and 2019, 10 consecutive patients with histologically confirmed HCC-CC received TARE of a targeted territory using glass microspheres as a primary initial treatment. Baseline demographics in addition to tumor distribution, Child Pugh score, and BCLC were recorded. Tumor response was assessed according to modified RECIST criteria. The HCC-CC cohort was matched to the HCC cohort, and objective response and survival analysis was performed.
Results: In the HCC-CC cohort, patients had a 70% objective response rate (ORR), and in the HCC cohort, patients had a 90% ORR after matching (p = 0.54). The median overall survival (OS) for HCC patients was 12.3 months (95% CI: 6.0–17.4 months) in the matched population, and for HCC-CC patients, the median OS was 15.2 months (95% CI: 2.7–20.2 months) (p = 0.98). The median progression-free survival (PFS) for HCC patients was 11.6 months (95% CI: 2.53–19.3 months) in the matched population, and for HCC-CC patients, the median PFS was 15.2 months (95% CI: 2.7–20.2 months) (p = 0.94). The median transplant-free survival (TFS) for HCC patients was 12.3 months (95% CI: 6.0–17.4 months) in the matched population, and for HCC-CC patients, the median TFS was 15.2 months (95% CI: 2.7–20.2 months) (p = 0.98).
Conclusions: While outcomes of combined HCC-CC are poor and optimal treatment remains undefined, TARE appears to represent an effective locoregional treatment with survival outcomes similar to that of HCC treated by TARE.

  • About this article
    Cite this article
    Wali Badar, Thuong Van Ha, Steven Zangan, Rakesh Navuluri, Anjana Pillai, Talia Baker, Osman Ahmed. 2020. Yttrium-90 Radioembolization Therapy for Combined Hepatocellular and Cholangiocarcinoma. Gastrointestinal Tumors. 7:8386 doi: 10.1159/000508386
    Wali Badar, Thuong Van Ha, Steven Zangan, Rakesh Navuluri, Anjana Pillai, Talia Baker, Osman Ahmed. 2020. Yttrium-90 Radioembolization Therapy for Combined Hepatocellular and Cholangiocarcinoma. Gastrointestinal Tumors. 7:8386 doi: 10.1159/000508386
    shu

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return